Lyra Therapeutics, Inc. (LYRA): Nasdaq/NYSE listing notice — Nasdaq notifies Lyra Therapeutics of delisting; company deemed a public shell

Lyra Therapeutics, Inc.

Nasdaq cites public shell status after suspension of lead drug LYR-210 and near-complete workforce reduction.
Nasdaq also cites non-compliance with minimum $2.5M equity listing rule.
Company has requested hearing to appeal delisting; stay in effect pending panel decision.
CEO and CFO now consultants; no ongoing operations after workforce reduction.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lyra Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5550(b)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101, 5550(b)

Exact text from the filing

In the Staff Determination Letter, Nasdaq stated that, pursuant to Listing Rule 5101, it believes the Company is a “public shell” and that the continued listing of its securities is no longer warranted.

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-041191

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.